Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249755 | 0.79 | NOS3 (0.39) | — | |
| SCHEMBL13662722 | 0.78 | ELANE (0.38) | TDO2 | |
| SCHEMBL13615801 | 0.77 | NOS3 (0.34) | — | |
| SCHEMBL13659737 | 0.76 | NOTUM (0.51) | — | |
| SCHEMBL20242125 | 0.75 | POLB (0.50) | — | |
| SCHEMBL20390956 | 0.75 | — | — | |
| SCHEMBL20242304 | 0.74 | NNMT (0.39) | — | |
| SCHEMBL13623576 | 0.74 | PDE10A (0.30) | — | |
| SCHEMBL20390801 | 0.74 | CHRNB2 (0.41) | — | |
| SCHEMBL31316711 | 0.74 | CHRNB2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CHRNA7 4815/4885TDO2 1844/4885 |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CHRNA7 4815/4885TDO2 1844/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CHRNA7 4827/4885TDO2 1956/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | CHRNA7 3347/4885TDO2 2056/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | CHRNA7 4815/4885TDO2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.